What is ReCode Therapeutics?
ReCode Therapeutics is a clinical-stage genetic medicines company dedicated to advancing targeted delivery of genetic therapies. Leveraging its proprietary SORT lipid nanoparticle platform, the company aims to precisely treat a range of rare and common diseases with enhanced efficacy. The company's focus on innovative delivery mechanisms positions it at the forefront of genetic medicine development.
How much funding has ReCode Therapeutics raised?
ReCode Therapeutics has raised a total of $415.4M across 6 funding rounds:
Angel/Seed
$2M
Series A
$80M
Private Equity
$15M
Series B
$260M
Other Financing Round
$29M
Debt
$29.4M
Angel/Seed (2019): $2M, investors not publicly disclosed
Series A (2020): $80M led by Vida Ventures, Colt Ventures, Osage University Partners, MPM BioImpact, Hunt Technology Ventures, and OrbiMed
Private Equity (2023): $15M supported by Cystic Fibrosis Foundation
Series B (2023): $260M featuring Colt Ventures, EcoR1 Capital, Sanofi Ventures, Superstring Capital, Solasta Ventures, Tekla Healthcare Opportunities, Vida Ventures, MPM BioImpact, Hunt Technology Ventures, Pfizer, OrbiMed, Osage University Partners, BLV, and NS Investment
Other Financing Round (2025): $29M, investors not publicly disclosed
Debt (2025): $29.4M, investors not publicly disclosed
Key Investors in ReCode Therapeutics
Colt Ventures
Colt Ventures is a diversified investment firm based in Dallas, TX, founded in 2003, that focuses on investments across various sectors including biotechnology, oil & gas, technology, real estate, consumer & retail, and financial services. The firm aims to make a meaningful impact on people's lives by sourcing and evaluating numerous deals in both private and public markets.
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector. The company aims to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation and developing new medicines.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi.
What's next for ReCode Therapeutics?
The substantial enterprise-level funding ReCode Therapeutics has garnered indicates a strategic phase of scaling and development. This capital infusion is expected to accelerate the advancement of its pipeline, potentially enabling further clinical trials and the expansion of its therapeutic reach. The company's commitment to precision medicine and its proprietary technology platform suggest a trajectory focused on bringing novel genetic therapies to patients with unmet medical needs.
See full ReCode Therapeutics company page
